Successful Combination Therapy of Cyclosporine and Methotrexate for Refractory Polymyositis with Anti-Jo-1 Antibody: A Case Report

Journal of Korean Medical Science

Volumn 18, Issue 1, 2003, Pages 131-134

  Chang, Hyun Kyu ^a   Lee, Deok Hee ^b  

^a Dankook University   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

Anti Jo 1 Antibody; Cyclosporine; Methotrexate; Polymyositis

Indexed keywords

ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; JO 1 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; AUTOANTIGEN; HISTIDINE TRANSFER RNA LIGASE; IMMUNOSUPPRESSIVE AGENT; JO-1 ANTIBODY;

ADULT; ANAMNESIS; ANTISYNTHETASE SYNDROME; ARTICLE; BIOSAFETY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG SAFETY; ELECTROMYOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG FUNCTION TEST; LUNG LAVAGE; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POLYMYOSITIS; REFRACTORY PERIOD; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME; BLOOD; DRUG COMBINATION; DRUG RESISTANCE; IMMUNOLOGY;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; CYCLOSPORINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HISTIDINE-TRNA LIGASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; POLYMYOSITIS;

EID: 0141958641     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2003.18.1.131     Document Type: Article

References (14)

1. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine 1991; 70: 360-74.
2. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984; 11: 663-5.
3. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000; 12: 492-7.
4. Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997; 26: 24-9.
5. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41: 392-9.
6. Mitsunaka H, Tokuda M, Hiraishi T, Dobashi H, Takahara J. Combined use of cyclosporine and methotrexate in refractory polymyositis. Scand J Rheumatol 2000; 29: 192-4.
7. Targoff IN. Immune manifestation of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 20: 857-80.
8. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, Miller FW. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-87.
9. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215-20.
10. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, Kita Y, Kawai M, Saito Y, Iwamoto I. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999; 26: 1527-33.
11. Tellus MM, Buchanan RR. Effective treatment of anti-Jo-1 antibody positive polymyositis with cyclosporine. Br J Rheumatol 1995; 34: 1187-8.
12. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-41.
13. Stein CM, Pincus T, Yocum D, Tugwell P, Wells G, Gluck O, Kraag G, Torley H, Tesser J, McKendry R, Brooks RH. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997; 40: 1843-51.
14. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, Bernstein BH. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436-43.